Lv0
0 积分 2025-11-12 加入
The Rise of “Ozempic Face”: Analyzing Trends and Treatment Challenges Associated with Rapid Facial Weight Loss Induced by GLP-1 Agonists
7个月前
已完结
As Ozempic’s Popularity Soars, Here’s What to Know About Semaglutide and Weight Loss
7个月前
已完结
Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review
7个月前
已完结
Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial
7个月前
已完结
Semaglutide for the treatment of obesity
7个月前
已完结
Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
7个月前
已完结
Safety of Semaglutide
7个月前
已完结
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
7个月前
已完结
Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review
7个月前
已完结
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
7个月前
已完结
皖公网安备34019202002308
